Pathogenicity and virulence of Clostridioides difficile

References

• Adams CM, Eckenroth BE, Putnam EE, et al. Structural and functional analysis of the CspB protease required for Clostridium spore germination. PLoS Pathog. 2013;9(2):e1003165.
   PubMed Web of Science ®Google Scholar
• ECDC, n.d. Clostridium difficile infections - facts and surveillance [WWW Document]. European Centre for Disease Prevention and Control [cited 2022 Mar 22]. Available from https://www.ecdc.europa.eu/en/Clostridium-difficile-infections/facts
   Google Scholar
• Liao F, Li W, Gu W, et al. A retrospective study of community-acquired Clostridium difficile infection in southwest China. Sci Rep. 2018;8(1):1–25.
   PubMedGoogle Scholar
• Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature rev Microbiol. 2009;7(7):526–536.
   PubMed Web of Science ®Google Scholar
• Cole SA, Stahl TJ. Persistent and recurrent Clostridium difficile colitis. Clin Colon Rectal Surg. 2015;28(02):65–69.
   PubMedGoogle Scholar
• Napolitano LM, Edmiston CE. Clostridium difficile disease: diagnosis, pathogenesis, and treatment update. Surgery. 2017;162(2):325–348.
   PubMed Web of Science ®Google Scholar
• Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8(10):e1002995.
   PubMed Web of Science ®Google Scholar
• Owens RC, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(s1):S19–31.
   PubMedGoogle Scholar
• Song JH, Kim YS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16–24.
   PubMed Web of Science ®Google Scholar
• CDC, 2019. Antibiotic-resistant Germs: new threats [WWW Document].Centers for Disease Control and Prevention [cited 2020 Oct 29]. Available from https://www.cdc.gov/drugresistance/biggest-threats.html
   Google Scholar
• He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109–113.
   PubMed Web of Science ®Google Scholar
• Curry SR, Marsh JW, Muto CA, et al. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol. 2007;45(1):215–221.
   PubMed Web of Science ®Google Scholar
• Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol. 2002;40(9):3470–3475.
   PubMed Web of Science ®Google Scholar
• Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–1084.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Johnson S, Rupnik M, et al. Clostridium difficile binary toxin CDT. Gut Microbes. 2014;5(1):15–27.
   PubMed Web of Science ®Google Scholar
• Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35(5):300.
   PubMed Web of Science ®Google Scholar
• Mansfield MJ, Tremblay BJ-M, Zeng J, et al. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin a and B. PLoS Pathog. 2020;16(12):e1009181.
   PubMed Web of Science ®Google Scholar
• U PHE. 2018. Clostridium difficile infection: mandatory surveillance 2017/18 summary of the mandatory surveillance annual epidemiological commentary 2017/18.
   Google Scholar
• GOV.UK, n.d. Clostridioides difficile: guidance, data and analysis [WWW Document]. [cited 2022 Mar 3]. Available from https://www.gov.uk/government/collections/Clostridium-difficile-guidance-data-and-analysis
   Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834.
   PubMed Web of Science ®Google Scholar
• Heimann SM, Cruz Aguilar MR, Mellinghof S, et al. Economic burden and cost-effective management of Clostridium difficile infections. Médecine et maladies infectieuses. 2018;48(1):23–29.
   PubMed Web of Science ®Google Scholar
• Reigadas Ramírez E, Bouza ES. Economic burden of Clostridium difficile infection in European Countries. Adv Exp Med Biol. 2018;1050:1–12.
   PubMed Web of Science ®Google Scholar
• Roldan GA, Cui AX, Pollock NR. Assessing the burden of Clostridium difficile infection in low- and middle-income countries. J Clin Microbiol. 2018;56(3). DOI:10.1128/JCM.01747-17
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol. 2019;266(2):461–467.
   PubMed Web of Science ®Google Scholar
• Paredes-Sabja D, Shen A, Sorg JA. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. 2014;22(7):406–416.
   PubMed Web of Science ®Google Scholar
• Coullon H, Candela T. Clostridioides difficile peptidoglycan modifications. Curr Opin Microbiol. 2022;65:156–161.
   PubMed Web of Science ®Google Scholar
• Janganan TK, Mullin N, Dafis-Sagarmendi A, et al. Architecture and self-assembly of Clostridium sporogenes and Clostridium botulinum spore surfaces illustrate a general protective strategy across spore formers. mSphere. 2020;5(4). DOI:10.1128/mSphere.00424-20
   PubMed Web of Science ®Google Scholar
• Deakin LJ, Clare S, Fagan RP, et al. The Clostridium difficile spo0a gene is a persistence and transmission factor. Infect Immun. 2012;80(8):2704–2711.
   PubMed Web of Science ®Google Scholar
• MacLeod-Glover N, Sadowski C Efficacy of cleaning products for C. difficile: environmental strategies to reduce the spread of Clostridium difficile-associated diarrhea in geriatric rehabilitation. Can Fam Physician. 2010 56(5):417–423.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Palacios A, LeJeune JT. Moist-heat resistance, spore aging, and superdormancy in Clostridium difficile. Appl Environ Microbiol. 2011;77(9):3085–3091.
   PubMed Web of Science ®Google Scholar
• Murray SG, Yim JWL, Croci R, et al. Using spatial and temporal mapping to identify nosocomial disease transmission of Clostridium difficile. JAMA Intern Med. 2017;177(12):1863–1865.
   PubMed Web of Science ®Google Scholar
• Burns DA, Heeg D, Cartman ST, et al. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One. 2011;6(9):e24894.
   PubMed Web of Science ®Google Scholar
• Merrigan M, Venugopal A, Mallozzi M, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol. 2010;192(19):4904–4911.
   PubMed Web of Science ®Google Scholar
• Donnelly ML, Fimlaid KA, Shen A. Characterization of Clostridium difficile spores lacking either SpoVAC or dipicolinic acid synthetase. J Bacteriol. 2016;198(11):1694–1707.
   PubMed Web of Science ®Google Scholar
• Setlow P. I will survive: DNA protection in bacterial spores. Trends Microbiol. 2007;15(4):172–180.
   PubMed Web of Science ®Google Scholar
• Setlow P. Spores of Bacillus subtilis: their resistance to and killing by radiation, heat and chemicals. J Appl Microbiol. 2006;101(3):514–525.
   PubMed Web of Science ®Google Scholar
• Nerber HN, Sorg JA, McClane BA. The small acid-soluble proteins of Clostridioides difficile are important for UV resistance and serve as a check point for sporulation. PLoS Pathog. 2021;17(9):e1009516.
   PubMed Web of Science ®Google Scholar
• Lee CD, Rizvi A, Edwards AN, et al. Genetic mechanisms governing sporulation initiation in Clostridioides difficile. Curr Opin Microbiol. 2022;66:32–38.
   PubMed Web of Science ®Google Scholar
• Shen A. Clostridioides difficile spore formation and germination: new insights and opportunities for intervention. Annu Rev Microbiol. 2020;74(1):545–566.
   PubMedGoogle Scholar
• Battistuzzi FU, Feijao A, Hedges SB. A genomic timescale of prokaryote evolution: insights into the origin of methanogenesis, phototrophy, and the colonization of land. BMC Evol Biol. 2004;4(1):44.
   PubMedGoogle Scholar
• Ramos-Silva P, Serrano M, Henriques AO. From root to tips: sporulation evolution and specialization in Bacillus subtilis and the intestinal pathogen Clostridioides difficile. Mol Biol Evol. 2019;36(12):2714–2736.
   PubMed Web of Science ®Google Scholar
• Fimlaid KA, Bond JP, Schutz KC, et al. Global analysis of the sporulation pathway of Clostridium difficile. PLoS Gene. 2013;9(8):e1003660.
   PubMed Web of Science ®Google Scholar
• Edwards AN, Wetzel D, DiCandia MA, et al. Three orphan Histidine kinases inhibit Clostridioides difficile sporulation. J Bacteriol. 2022;204(5). DOI:10.1128/jb.00106-22
   Web of Science ®Google Scholar
• Martins D, DiCandia MA, Mendes AL, et al. CD25890, a conserved protein that modulates sporulation initiation in Clostridioides difficile. Sci Rep. 2021;11(1):1–15.
   PubMed Web of Science ®Google Scholar
• Nawrocki KL, Edwards AN, Daou N, et al. CodY-dependent regulation of sporulation in Clostridium difficile. J Bacteriol. 2016;198(15):2113–2130.
   PubMed Web of Science ®Google Scholar
• Wetzel D, McBride SM. The impact of pH on Clostridioides difficile sporulation and physiology. Appl Environ Microbiol. 2019. DOI:10.1128/AEM.02706-19
   Web of Science ®Google Scholar
• Antunes A, Camiade E, Monot M, et al. Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile. Nucleic Acids Res. 2012;40(21):10701–10718.
   PubMed Web of Science ®Google Scholar
• Edwards AN, Tamayo R, McBride SM. A novel regulator controls Clostridium difficile sporulation, motility and toxin production. Mol Microbiol. 2016;100(6):954–971.
   PubMed Web of Science ®Google Scholar
• Rocha-Estrada J, Aceves-Diez AE, Guarneros G, et al. The RNPP family of quorum-sensing proteins in Gram-positive bacteria. Appl Microbiol Biotechnol. 2010;87(3):913–923.
   PubMed Web of Science ®Google Scholar
• Dembek M, Barquist L, Boinett CJ, et al. High-throughput analysis of gene essentiality and sporulation in Clostridium difficile. MBio. 2015;6(2). DOI:10.1128/mBio.02383-14
   PubMed Web of Science ®Google Scholar
• Oliveira PH, Ribis JW, Garrett EM, et al. Epigenomic characterization of Clostridioides difficile finds a conserved DNA methyltransferase that mediates sporulation and pathogenesis. Nat Microbiol. 2020;5(1):166–180.
   PubMed Web of Science ®Google Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512.
   PubMed Web of Science ®Google Scholar
• Gerskowitch VP, Russell RI. The physiology of bile acids in duodenum and jejunum. Scott Med J. 1973;18(5):138–141.
   PubMed Web of Science ®Google Scholar
• de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(5):657–669.
   PubMed Web of Science ®Google Scholar
• Kevorkian Y, Shen A, Schneewind O. Revisiting the role of Csp family proteins in regulating Clostridium difficile spore germination. J Bacteriol. 2017;199(22). DOI:10.1128/JB.00266-17
   PubMed Web of Science ®Google Scholar
• Francis MB, Sorg JA, Limbago BM. Dipicolinic acid release by germinating Clostridium difficile spores occurs through a mechanosensing mechanism. mSphere. 2016;1(6). DOI:10.1128/mSphere.00306-16
   PubMed Web of Science ®Google Scholar
• Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012;20(7):313–319.
   PubMed Web of Science ®Google Scholar
• Pike CM, Theriot CM. Mechanisms of colonization resistance against Clostridioides difficile. J Infect Dis. 2020;223(Supplement_3):S194–200.
   Google Scholar
• Dembek M, Stabler RA, Witney AA, et al. Transcriptional analysis of temporal gene expression in germinating Clostridium difficile 630 endospores. PLoS One. 2013;8(5):e64011.
   PubMed Web of Science ®Google Scholar
• Lawley TD, Clare S, Walker AW, et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun. 2009;77(9):3661–3669.
   PubMed Web of Science ®Google Scholar
• Castro-Córdova P, Mora-Uribe P, Reyes-Ramírez R, et al. Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection. Nat Commun. 2021;12(1):1–18.
   PubMed Web of Science ®Google Scholar
• Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6.
   PubMed Web of Science ®Google Scholar
• Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629–635.
   PubMed Web of Science ®Google Scholar
• Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol. 2011;60(8):1070–1079.
   PubMed Web of Science ®Google Scholar
• Jank T, Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol. 2008;16(5):222–229.
   PubMed Web of Science ®Google Scholar
• Bouillaut L, Dubois T, Sonenshein AL, et al. Integration of metabolism and virulence in Clostridium difficile. Res Microbiol. 2015;166(4):375–383. DOI:10.1016/j.resmic.2014.10.002.
   PubMed Web of Science ®Google Scholar
• Donnelly ML, Shrestha S, Ribis JW, et al. Development of a dual-fluorescent-reporter system in Clostridioides difficile Reveals a Division of Labor between Virulence and Transmission Gene Expression. mSphere. 2022;7(3). DOI:10.1128/msphere.00132-22
   PubMed Web of Science ®Google Scholar
• Govind R, Fitzwater L, Nichols R. Observations on the role of TcdE isoforms in Clostridium difficile toxin secretion. J Bacteriol. 2015;197(15):2600–2609.
   PubMed Web of Science ®Google Scholar
• Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA. 2001;98(10):5844–5849.
   PubMed Web of Science ®Google Scholar
• Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol. 2007;64(5):1274–1288.
   PubMed Web of Science ®Google Scholar
• Majumdar A, Govind R. Regulation of Clostridioides difficile toxin production. Curr Opin Microbiol. 2022;65:95–100.
   PubMed Web of Science ®Google Scholar
• Pruitt RN, Chambers MG, Ng KK-S, et al., 2010. Structural organization of the functional domains of Clostridium difficile toxins a and B. Proceedings of the National Academy of Sciences 107, 13467–13472. 10.1073/pnas.1002199107
   Google Scholar
• Hartley-Tassell LE, Awad MM, Seib KL, et al. Lectin activity of the TcdA and TcdB toxins of Clostridium difficile. Infect Immun. 2018;87(3). DOI:10.1128/IAI.00676-18
   Web of Science ®Google Scholar
• Pothoulakis C, Gilbert RJ, Cladaras C, et al. Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin a. J Clin Invest. 1996;98(3):641–649.
   PubMed Web of Science ®Google Scholar
• Na X, Kim H, Moyer M, et al. gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infection and immunity. 2008;76(7): 2862–2871.
   Web of Science ®Google Scholar
• Tao L, Tian S, Zhang J, et al. Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to Clostridium difficile toxin a entry into cells. Nat Microbiol. 2019;4(10):1760–1769.
   PubMed Web of Science ®Google Scholar
• Schöttelndreier D, Langejürgen A, Lindner R, et al. Low density Lipoprotein Receptor-related Protein-1 (LRP1) is involved in the uptake of Clostridioides difficile toxin a and serves as an internalizing receptor. Front Cell Infect Microbiol. 2020;10. DOI:10.3389/fcimb.2020.565465.
   PubMed Web of Science ®Google Scholar
• Pan Z, Zhang Y, Luo J, et al. Functional analyses of epidemic Clostridioides difficile toxin B variants reveal their divergence in utilizing receptors and inducing pathology. PLoS Pathog. 2021;17(1):e1009197.
   PubMed Web of Science ®Google Scholar
• Yuan P, Zhang H, Cai C, et al. Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B. Cell Res. 2015;25(2):157–168.
   PubMed Web of Science ®Google Scholar
• Chen P, Zeng J, Liu Z, et al. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection. Nat Commun. 2021;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Jiang M, Shin J, Simeon R, et al. Structural dynamics of receptor recognition and pH-induced dissociation of full-length Clostridioides difficile Toxin B. PLoS Biol. 2022;20(3):e3001589.
   PubMed Web of Science ®Google Scholar
• Terada N, Ohno N, Murata S, et al. Immunohistochem-ical study of NG2 chondroitin sulfate proteoglycan expression in the small and large intestines. Histochem Cell Biol. 2006;126(4):483–490.
   PubMed Web of Science ®Google Scholar
• LaFrance ME, Farrow MA, Chandrasekaran R, et al. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proceedings of the National Academy of Sciences. 2015;112(22):7073–7078.
   PubMed Web of Science ®Google Scholar
• Tao L, Zhang J, Meraner P, et al. Frizzled are colonic epithelial receptors for Clostridium difficile toxin B. Nature. 2016;538(7625):350–355.
   PubMed Web of Science ®Google Scholar
• Chen P, Tao L, Wang T, et al. Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B. Science. 2018;360(6389):664–669.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang Q, Zhang X, et al. TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile. Cell. 2022;185(6):980–994.e15.
   PubMed Web of Science ®Google Scholar
• Papatheodorou P, Zamboglou C, Genisyuerek S, et al. Clostridial glucosylating toxins enter cells via Clathrin-mediated endocytosis. PLoS One. 2010;5.(5):e10673.
   PubMed Web of Science ®Google Scholar
• Barth H, Pfeifer G, Hofmann F, et al. Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells. J Biol Chem. 2001;276(14):10670–10676.
   PubMed Web of Science ®Google Scholar
• Qa’Dan M, Spyres LM, Ballard JD. pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun. 2000;68(5):2470–2474.
   PubMed Web of Science ®Google Scholar
• Egerer M, Giesemann T, Herrmann C, et al. Autocatalytic Processing of Clostridium difficile toxin B: binding of inositol hexakisphosphate*. J Biol Chem. 2009;284:3389–3395.
   PubMed Web of Science ®Google Scholar
• Oezguen N, Power TD, Urvil P, et al. Clostridial toxins. Gut Microbes. 2012;3(1):35–41.
   PubMed Web of Science ®Google Scholar
• Bilverstone TW, Garland M, Cave RJ, et al. The glucosyltransferase activity of C. difficile toxin B is required for disease pathogenesis. PLoS Pathog. 2020;16(9):e1008852.
   PubMed Web of Science ®Google Scholar
• Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins a and B: new insights into structure and function. Glycobiology. 2007;17(4):15R–22R.
   PubMed Web of Science ®Google Scholar
• Just I, Selzer J, Wilm M, et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995;375(6531):500–503.
   PubMed Web of Science ®Google Scholar
• Gerhard R, Nottrott S, Schoentaube J, et al. Glucosylation of Rho GTPases by Clostridium difficile toxin a triggers apoptosis in intestinal epithelial cells. J Med Microbiol. 2008;57(6):765–770.
   PubMed Web of Science ®Google Scholar
• Janoir C, 2016 37 13–24 . Virulence factors of Clostridium difficile and their role during infection. Anaerobe [].
   PubMed Web of Science ®Google Scholar
• Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247–263.
   PubMed Web of Science ®Google Scholar
• Madan R, Petri WA. Immune responses to Clostridium difficile infection. Trends Mol Med. 2012;18(11):658–666.
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Lockwood DE, Richardson SH, et al. Biological activities of toxins A and B of Clostridium difficile. Infect Immun. 1982;35(3):1147–1150.
   PubMed Web of Science ®Google Scholar
• Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Inter J Infect Dis. 2007;11(1):5–10.
   PubMed Web of Science ®Google Scholar
• Kuehne SA, Collery MM, Kelly ML, et al. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis. 2014;209(1):83–86.
   PubMed Web of Science ®Google Scholar
• Carter GP, Chakravorty A, Nguyen TAP, et al. Defining the Roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. MBio. 2015;6(3). DOI:10.1128/mBio.00551-15
   Web of Science ®Google Scholar
• Li Z, Lee K, Rajyaguru U, et al. Ribotype classification of Clostridioides difficile isolates is not predictive of the amino acid sequence diversity of the toxin virulence factors TcdA and TcdB. Front Microbiol. 2020;11. DOI:10.3389/fmicb.2020.01310
   Google Scholar
• Shen W-J, Deshpande A, Hevener KE, et al. Constitutive expression of the cryptic vanGcd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. J Antimicrob Chemother. 2020;75(4):859–867.
   PubMed Web of Science ®Google Scholar
• Govind R, Vediyappan G, Rolfe RD, et al. Evidence that Clostridium difficile TcdC is a membrane-associated protein. J Bacteriol. 2006;188(10):3716–3720.
   PubMed Web of Science ®Google Scholar
• Carter GP, Douce GR, Govind R, et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 2011;7(10):e1002317.
   PubMed Web of Science ®Google Scholar
• Paiva AMO, Jong LD, Friggen AH, et al. The C-terminal domain of Clostridioides difficile TcdC is exposed on the bacterial cell surface. J Bacteriol. 2020. DOI:10.1128/JB.00771-19
   Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–2449.
   PubMed Web of Science ®Google Scholar
• Anderson DM, Sheedlo MJ, Jensen JL, et al. Structural insights into the transition of Clostridioides difficile binary toxin from prepore to pore. Nat Microbiol. 2020;5(1):102–107.
   PubMed Web of Science ®Google Scholar
• Xu X, Godoy-Ruiz R, Adipietro KA, et al., 2020. Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly. Proceedings of the National Academy of Sciences 117, 1049–1058. 10.1073/pnas.1919490117
   Google Scholar
• Papatheodorou P, Carette JE, Bell GW, et al. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci U S A. 2011;108(39):16422–16427.
   PubMed Web of Science ®Google Scholar
• Hemmasi S, Czulkies BA, Schorch B, et al. Interaction of the Clostridium difficile binary toxin CDT and its host cell receptor, Lipolysis-stimulated Lipoprotein Receptor (LSR). J Biol Chem. 2015;290(22):14031–14044.
   PubMed Web of Science ®Google Scholar
• Ernst K, Langer S, Kaiser E, et al. Cyclophilin-facilitated membrane translocation as pharmacological target to prevent intoxication of mammalian cells by binary clostridial actin ADP-ribosylated toxins. J Mol Biol Elucidation Protein Translocation Pathways (Part II). 2015;427(6):1224–1238.
   Google Scholar
• Aktories K, Lang AE, Schwan C, et al. Actin as target for modification by bacterial protein toxins. FEBS J. 2011;278(23):4526–4543.
   PubMed Web of Science ®Google Scholar
• Schwan C, Stecher B, Tzivelekidis T, et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 2009;5(10):e1000626.
   PubMed Web of Science ®Google Scholar
• Akhmanova A, Steinmetz MO. Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol. 2015;16(12):711–726.
   PubMed Web of Science ®Google Scholar
• Schwan C, Kruppke AS, Nölke T, et al. Clostridium difficile toxin CDT hijacks microtubule organization and reroutes vesicle traffic to increase pathogen adherence. Proc Natl Acad Sci U S A. 2014;111(6):2313–2318.
   PubMed Web of Science ®Google Scholar
• Lyon SA, Hutton ML, Rood JI, et al. CdtR regulates TcdA and TcdB production in Clostridium difficile. PLoS Pathog. 2016;12(7):e1005758.
   PubMed Web of Science ®Google Scholar
• Carter GP, Lyras D, Allen DL, et al. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol. 2007;189(20):7290–7301.
   PubMed Web of Science ®Google Scholar
• Eckert C, Emirian A, Le Monnier A, et al. Prevalence and pathogenicity of binary toxin–positive Clostridium difficile strains that do not produce toxins a and B. New Microbes New Infect. 2015;3:12–17.
   PubMedGoogle Scholar
• Cowardin CA, Buonomo EL, Saleh MM, et al. The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol. 2016;1(8):1–10.
   Web of Science ®Google Scholar
• Marquardt I, Jakob J, Scheibel J, et al. Clostridioides difficile toxin CDT induces cytotoxic responses in human mucosal-associated invariant T (MAIT) cells. Front Microbiol. 2021;12. DOI:10.3389/fmicb.2021.752549.
   Web of Science ®Google Scholar
• Dingle KE, Didelot X, Ansari MA, et al. Recombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing. J Infect Dis. 2013;207:675–686.
   PubMed Web of Science ®Google Scholar
• Fagan RP, Fairweather NF. Biogenesis and functions of bacterial S-layers. Nature rev Microbiol. 2014;12(3):211–222.
   PubMed Web of Science ®Google Scholar
• Calabi E, Ward S, Wren B, et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol. 2001;40(5):1187–1199.
   PubMed Web of Science ®Google Scholar
• Fagan RP, Albesa-Jové D, Qazi O, et al. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol. 2009;71(5):1308–1322.
   PubMed Web of Science ®Google Scholar
• Mori N, Takahashi T. Characteristics and immunological roles of surface layer proteins in Clostridium difficile. Ann Lab Med. 2018;38(3):189–195.
   PubMed Web of Science ®Google Scholar
• Kirk JA, Gebhart D, Buckley AM, et al. New Class of precision antimicrobials redefines role of Clostridium difficile S-layer in virulence and viability. Sci Transl Med. 2017;9(406). DOI:10.1126/scitranslmed.aah6813
   PubMed Web of Science ®Google Scholar
• Calabi E, Calabi F, Phillips AD, et al. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun. 2002;70(10):5770–5778.
   PubMed Web of Science ®Google Scholar
• Merrigan MM, Venugopal A, Roxas JL, et al. Surface-layer protein a (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One. 2013;8(11):e78404.
   PubMed Web of Science ®Google Scholar
• Willing SE, Candela T, Shaw HA, et al. Clostridium difficile surface proteins are anchored to the cell wall using CWB2 motifs that recognise the anionic polymer PSII. Mol Microbiol. 2015;96(3):596–608.
   PubMed Web of Science ®Google Scholar
• Knight DR, Elliott B, Chang BJ, et al. Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev. 2015;28(3):721–741.
   PubMed Web of Science ®Google Scholar
• Wright A, Drudy D, Kyne L, et al. Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol. 2008;57(6):750–756. n.d. DOI:10.1099/jmm.0.47532-0.
   PubMed Web of Science ®Google Scholar
• Bradshaw WJ, Kirby JM, Roberts AK, et al. Cwp2 from Clostridium difficile exhibits an extended three domain fold and cell adhesion in vitro. FEBS J. 2017;284(17):2886–2898.
   PubMed Web of Science ®Google Scholar
• Kirby JM, Ahern H, Roberts AK, et al. Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem. 2009;284(50):34666–34673.
   PubMed Web of Science ®Google Scholar
• Waligora A-J, Hennequin C, Mullany P, et al. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun. 2001;69(4):2144–2153.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Rao F, Chen Z, et al. The cwp66 gene affects cell adhesion, stress tolerance, and antibiotic resistance in Clostridioides difficile. Microbiol Spectr. 2022;10(2). DOI:10.1128/spectrum.02704-21
   Web of Science ®Google Scholar
• Peltier J, Courtin P, El Meouche I, et al. Clostridium difficile has an original peptidoglycan structure with a high level of N-Acetylglucosamine deacetylation and mainly 3-3 cross-links. J Biol Chem. 2011;286(33):29053–29062.
   PubMed Web of Science ®Google Scholar
• Zhu D, Bullock J, He Y, et al. Cwp22, a novel peptidoglycan cross-linking enzyme, plays pleiotropic roles in Clostridioides difficile. Environ Microbiol. 2019;21(8):3076–3090.
   PubMed Web of Science ®Google Scholar
• Wydau-Dematteis S, Meouche IE, Courtin P, et al. Cwp19 is a novel lytic transglycosylase involved in stationary-phase autolysis resulting in toxin release in Clostridium difficile. MBio. 2018;9(3). DOI:10.1128/mBio.00648-18
   PubMed Web of Science ®Google Scholar
• Emerson JE, Reynolds CB, Fagan RP, et al. A novel genetic switch controls phase variable expression of CwpV, a Clostridium difficile cell wall protein. Mol Microbiol. 2009;74(3):541–556.
   PubMed Web of Science ®Google Scholar
• Dembek M, Reynolds CB, Fairweather NF. Clostridium difficile cell wall protein CwpV undergoes enzyme-independent intramolecular autoproteolysis. J Biol Chem. 2012;287(2):1538–1544.
   PubMed Web of Science ®Google Scholar
• Reynolds CB, Emerson JE, de la Riva L, et al. The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog. 2011;7(4):e1002024.
   PubMed Web of Science ®Google Scholar
• Arato V, Gasperini G, Giusti F, et al. Dual role of the colonization factor CD2831 in Clostridium difficile pathogenesis. Sci Rep. 2019;9(1):1–12.
   PubMedGoogle Scholar
• Tulli L, Marchi S, Petracca R, et al. CbpA: a novel surface exposed adhesin of Clostridium difficile targeting human collagen. Cell Microbiol. 2013;15:1674–1687.
   PubMed Web of Science ®Google Scholar
• Ragland SA, Criss AK, Bliska JB. From bacterial killing to immune modulation: recent insights into the functions of lysozyme. PLoS Pathog. 2017;13(9):e1006512.
   PubMed Web of Science ®Google Scholar
• Lanzoni-Mangutchi P, Banerji O, Wilson J, et al. Structure and assembly of the S-layer in C. difficile. Nat Commun. 2022;13(1):1–13.
   PubMed Web of Science ®Google Scholar
• Ho TD, Williams KB, Chen Y, et al. Clostridium difficile extracytoplasmic function σ factor σV regulates lysozyme resistance and is necessary for pathogenesis in the hamster model of infection. Infect Immun. 2014;82(6):2345–2355.
   PubMed Web of Science ®Google Scholar
• Kaus GM, Snyder LF, Müh U, et al. Lysozyme resistance in C. difficile is dependent on two peptidoglycan deacetylases. bioRxiv. 2020. DOI:10.1101/2020.07.17.209676
   Google Scholar
• Callewaert L, Michiels CW, 2010 35 127–160 . Lysozymes in the animal kingdom. J Biosci.].
   PubMed Web of Science ®Google Scholar
• Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect. 2018;24(5):476–482.
   PubMed Web of Science ®Google Scholar
• Frost LR, Cheng JKJ, Unnikrishnan M. Clostridioides difficile biofilms: a mechanism of persistence in the gut? PLoS Pathog. 2021;17(3):e1009348.
   PubMed Web of Science ®Google Scholar
• Ðapa T, Ng R, Leuzzi YK, et al. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol. 2012;195(3):545–555.
   PubMed Web of Science ®Google Scholar
• Bordeleau E, Purcell EB, Lafontaine DA, et al. Cyclic Di-GMP Riboswitch-regulated Type IV pili contribute to aggregation of Clostridium difficile. J Bacteriol. 2014;197(5):819–832.
   PubMed Web of Science ®Google Scholar
• Poquet I, Saujet L, Canette A, et al. Clostridium difficile biofilm: remodeling metabolism and cell surface to build a sparse and heterogeneously aggregated architecture. Front Microbiol. 2018;9. DOI:10.3389/fmicb.2018.02084
   PubMed Web of Science ®Google Scholar
• Jain S, Smyth D, O’Hagan BMG, et al. Inactivation of the dnaK gene in Clostridium difficile 630 δerm yields a temperature-sensitive phenotype and increases biofilm-forming ability. Sci Rep. 2017;7(1):1–13.
   PubMedGoogle Scholar
• Walter BM, Cartman ST, Minton NP, et al. The SOS response master regulator LexA is associated with sporulation, motility and biofilm formation in Clostridium difficile. PLoS One. 2015;10(12):e0144763.
   PubMed Web of Science ®Google Scholar
• Taggart MG, Snelling WJ, Naughton PJ, et al. Biofilm regulation in Clostridioides difficile: novel systems linked to hypervirulence. PLoS Pathog. 2021;17(9):e1009817.
   PubMed Web of Science ®Google Scholar
• Soavelomandroso AP, Gaudin F, Hoys S, et al. Biofilm structures in a mono-associated mouse model of Clostridium difficile infection. Front Microbiol. 2017;8. DOI:10.3389/fmicb.2017.02086
   PubMed Web of Science ®Google Scholar
• Semenyuk EG, Poroyko VA, Johnston PF, et al. Analysis of bacterial communities during Clostridium difficile infection in the mouse. Infect Immun. 2015;83(11):4383–4391.
   PubMed Web of Science ®Google Scholar
• Dawson LF, Valiente E, Faulds-Pain A, et al. Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS One. 2012;7(12):e50527.
   PubMed Web of Science ®Google Scholar
• Boekhoud IM, Hornung BVH, Sevilla E, et al. Plasmid-mediated metronidazole resistance in Clostridioides difficile. Nat Commun. 2020;11(1):1–12.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Wu X, Huo W, et al. Chromosomal resistance to metronidazole in Clostridioides difficile can be mediated by epistasis between iron homeostasis and oxidoreductases. Antimicrob Agents Chemother. 2020;64(8). bioRxiv 2020.03.04.977868. DOI:10.1101/2020.03.04.977868.
   PubMed Web of Science ®Google Scholar
• Leeds JA, Sachdeva M, Mullin S, et al. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother. 2014;69(1):41–44.
   PubMed Web of Science ®Google Scholar
• Sassi M, Guérin F, Lesec L, et al. Genetic characterization of a VanG-type vancomycin-resistant Enterococcus faecium clinical isolate. J Antimicrob Chemother. 2018;73(4):852–855.
   PubMed Web of Science ®Google Scholar
• Pu M, Cho JM, Cunningham SA, et al. Plasmid acquisition alters vancomycin susceptibility in Clostridioides difficile. Gastroenterology. 2021;160(3):941–945.e8.
   PubMed Web of Science ®Google Scholar
• Wasels F, Kuehne SA, Cartman ST, et al. Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro. Antimicrob Agents Chemother. 2015;59(3):1794–1796.
   PubMed Web of Science ®Google Scholar
• Ducarmon QR, Zwittink RD, Hornung BVH, et al. Gut microbiota and colonization resistance against bacterial enteric infection. Microbiol Mol Biol Rev. 2019;83(3). DOI:10.1128/MMBR.00007-19
   PubMed Web of Science ®Google Scholar
• Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–208.
   PubMed Web of Science ®Google Scholar
• Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48.
   PubMed Web of Science ®Google Scholar
• Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection. Antimicrob Agents Chemother. 2020;64(4). DOI:10.1128/AAC.02169-19
   Web of Science ®Google Scholar
• Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota following a single dose of Clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2011;80(1):62–73.
   PubMed Web of Science ®Google Scholar
• Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection. Anaerobe. 2017;48:147–151.
   PubMed Web of Science ®Google Scholar
• Nicholson MR, Thomsen IP, Slaughter JC, et al. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60(1):18–22.
   PubMed Web of Science ®Google Scholar
• Peng Z, Jin D, Kim HB, et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol. 2017;55(7):1998–2008.
   PubMed Web of Science ®Google Scholar
• Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Advances Infect. 2016;3(1):23–42.
   PubMed Web of Science ®Google Scholar
• Farrow KA, Lyras D, Rood JI. The macrolide-lincosamide-streptogramin B resistance determinant from Clostridium difficile 630 contains two erm(b) genes. Antimicrob Agents Chemother. 2000;44(2):411–413.
   PubMed Web of Science ®Google Scholar
• Dzyubak E, Yap M-NF. The expression of antibiotic resistance methyltransferase correlates with mRNA stability independently of ribosome stalling. Antimicrob Agents Chemother. 2016;60(12):7178–7188.
   PubMed Web of Science ®Google Scholar
• Spigaglia P, Barbanti F, Mastrantonio P, et al. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother. 2011;66(10):2227–2234. DOI:10.1093/jac/dkr292.
   PubMed Web of Science ®Google Scholar
• Dong D, Chen X, Jiang C, et al. Genetic analysis of Tn916-like elements conferring tetracycline resistance in clinical isolates of Clostridium difficile. Int J Antimicrob Agents. 2014;43(1):73–77.
   PubMed Web of Science ®Google Scholar
• Dridi L, Tankovic J, Burghoffer B, et al. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002;46(11):3418–3421.
   PubMed Web of Science ®Google Scholar
• Cruz MP Fidaxomicin (Dificid), a novel oral macrocyclic antibacterial agent for the treatment of Clostridium difficile-associated diarrhea in adults. P T. 2012 37(5):278–281.
   PubMedGoogle Scholar
• Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;2017(3). DOI:10.1002/14651858.CD004610.pub5
   Google Scholar
• NICE, 2021. Recommendations | Clostridioides difficile infection: antimicrobial prescribing | Guidance | NICE [WWW Document]. [cited 2022 Apr 13] Available from https://www.nice.org.uk/guidance/ng199/chapter/Recommendations
   Google Scholar
• Banawas SS, 2018 8414257 . Clostridium difficile infections: a Global overview of drug sensitivity and resistance mechanisms [WWW Document]. BioMed Research International []
   PubMed Web of Science ®Google Scholar
• Lynch T, Chong P, Zhang J, et al. Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One. 2013;8(1):e53757.
   PubMed Web of Science ®Google Scholar
• Lin W, Das K, Degen D, et al. Structural basis of transcription inhibition by fidaxomicin (lipiarmycin a3). Mol Cell. 2018;70(1):60–71.e15.
   PubMed Web of Science ®Google Scholar
• Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis. 2012;54(4):568–574.
   PubMed Web of Science ®Google Scholar
• Schwanbeck J, Riedel T, Laukien F, et al. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB. J Antimicrob Chemother. 2019;74(1):6–10.
   PubMed Web of Science ®Google Scholar
• Patel S, Preuss CV, Bernice F. Vancomycin in: StatPearls. StatPearls Publishing, Treasure Island (FL); 2020.
   Google Scholar
• Saha S, Kapoor S, Tariq R, et al. Increasing antibiotic resistance in Clostridioides difficile: a systematic review and meta-analysis. Anaerobe. 2019;58:35–46. ASA2018: DOI:10.1016/j.anaerobe.2019.102072.
   PubMed Web of Science ®Google Scholar
• Sebaihia M, Wren BW, Mullany P, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet. 2006;38(7):779–786.
   PubMed Web of Science ®Google Scholar
• Darkoh C, Keita K, Odo C, et al. Emergence of Clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin. Clin Infect Dis. 2022;74(1):120–126.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lattimer LDN, Stephen S, et al. Fecal microbiota transplantation: a review of emerging indications beyond relapsing Clostridium difficile toxin colitis. Gastroenterol Hepatol (N Y). 2015 11(1):24–32.
   PubMedGoogle Scholar
• Basson AR, Zhou Y, Seo B, et al. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res. 2020;226:1–11.
   PubMed Web of Science ®Google Scholar
• Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479–493.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M et al, et al., 2013 368 5 407–415 . Duodenal infusion of donor feces for recurrent Clostridium difficile []. [].
   Google Scholar
• Nowak A, Hedenstierna M, Ursing J, et al. Efficacy of routine fecal microbiota transplantation for treatment of recurrent Clostridium difficile infection: a retrospective cohort study. Int J Microbiol. 2019;2019:1–7.
   Web of Science ®Google Scholar
• Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152(4):799–811.e7.
   PubMed Web of Science ®Google Scholar
• Sbahi H, Palma JAD. Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders. BMJ Open Gastroenterol. 2016;3(1):e000087.
   PubMedGoogle Scholar
• Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2016;9(2):229–239.
   PubMed Web of Science ®Google Scholar
• McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile Infection: lessons learned from a Phase 2 trial. Clin Infect Dis. 2021;72(12):2132–2140.
   PubMed Web of Science ®Google Scholar
• Dsouza M, Menon R, Crossette E, et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe. 2022;30(4):583–598.e8.
   PubMed Web of Science ®Google Scholar
• Salmond GPC, Fineran PC. A century of the phage: past, present and future. Nature Rev Microbiol. 2015;13(12):777–786.
   PubMed Web of Science ®Google Scholar
• Doron S, Melamed S, Ofir G, et al. Systematic discovery of antiphage defense systems in the microbial pangenome. Science. 2018;359(6379). DOI:10.1126/science.aar4120
   Web of Science ®Google Scholar
• Tal N, Sorek R. SnapShot: bacterial immunity. Cell. 2022;185(3):578.
   PubMed Web of Science ®Google Scholar
• Koonin EV, Krupovic M. Phages build anti-defence barriers. Nat Microbiol. 2020;5(1):8–9.
   PubMed Web of Science ®Google Scholar
• Hampton HG, Watson BNJ, Fineran PC. The arms race between bacteria and their phage foes. Nature. 2020;577(7790):327–336.
   PubMed Web of Science ®Google Scholar
• Fortier L-C, Moineau S. Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol. 2007;73(22):7358–7366.
   PubMed Web of Science ®Google Scholar
• Meader E, Mayer MJ, Gasson MJ, et al. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe. 2010;16(6):549–554.
   PubMed Web of Science ®Google Scholar
• Hargreaves KR, Clokie MRJ. Clostridium difficile phages: still difficult? Front Microbiol. 2014;5. DOI:10.3389/fmicb.2014.00184
   PubMed Web of Science ®Google Scholar
• Dowah ASA, Xia G, Ali AAK, et al. The structurome of a Clostridium difficile phage and the remarkable accurate prediction of its novel phage receptor-binding protein. bioRxiv. 2021. DOI:10.1101/2021.07.05.451159
   Google Scholar
• Phothichaisri W, Ounjai P, Phetruen T, et al. Characterization of bacteriophages infecting clinical isolates of Clostridium difficile. Front Microbiol. 2018;9. DOI:10.3389/fmicb.2018.01701
   PubMed Web of Science ®Google Scholar
• Royer ALM, Umansky AA, Allen M-M, et al. The Clostridioides difficile S-layer protein a (SlpA) serves as a general phage receptor. bioRxiv. 2022. DOI:10.1101/2022.09.19.508581
   Google Scholar
• Whittle MJ, Bilverstone TW, Esveld RJ van, et al. A novel bacteriophage with broad host range against Clostridioides difficile ribotype 078 supports SlpA as the likely phage receptor. Microbiol Spectr. 2022;10(1). DOI:10.1128/spectrum.02295-21
   PubMed Web of Science ®Google Scholar
• Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2015. DOI:10.1128/AAC.01774-15
   PubMed Web of Science ®Google Scholar
• Nale JY, Redgwell TA, Millard A, et al. Efficacy of an optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation model. Antibiotics. 2018;7(1):13.
   Google Scholar
• Gebhart D, Lok S, Clare S, et al. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity. MBio. 2015;6(2). DOI:10.1128/mBio.02368-14
   PubMed Web of Science ®Google Scholar
• Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–733.
   PubMed Web of Science ®Google Scholar
• Selle K, Fletcher JR, Tuson H, et al. In Vivo targeting of Clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials. MBio. 2020;11(2). DOI:10.1128/mBio.00019-20
   PubMed Web of Science ®Google Scholar
• McCallin S, Alam Sarker S, Barretto C, et al. Safety analysis of a Russian phage cocktail: from MetaGenomic analysis to oral application in healthy human subjects. Virology. 2013;443(2):187–196.
   PubMed Web of Science ®Google Scholar
• Park K, Cha KE, Myung H. Observation of inflammatory responses in mice orally fed with bacteriophage T7. J Appl Microbiol. 2014;117(3):627–633.
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol. 2010;300(6):357–362.
   PubMed Web of Science ®Google Scholar
• Mayer MJ, Garefalaki V, Spoerl R, et al. Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol. 2011;193(19):5477–5486.
   PubMed Web of Science ®Google Scholar
• Phothichaisri W, Chankhamhaengdecha S, Janvilisri T, et al. Potential role of the host-derived cell-wall binding domain of endolysin CD16/50L as a molecular anchor in preservation of uninfected Clostridioides difficile for new rounds of phage infection. Microbiol Spectr. 2022;10(2). DOI:10.1128/spectrum.02361-21
   PubMed Web of Science ®Google Scholar
• Wang Q, Euler CW, Delaune A, et al. Using a novel lysin to help control Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(12):7447–7457.
   PubMed Web of Science ®Google Scholar
• Orth P, Xiao L, Hernandez LD, et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014;289(26):18008–18021.
   PubMed Web of Science ®Google Scholar
• Warn P, Thommes P, Sattar A, et al. Disease progression and resolution in rodent models of Clostridium difficile infection and impact of antitoxin antibodies and vancomycin. Antimicrob Agents Chemother. 2016;60(11):6471–6482.
   PubMed Web of Science ®Google Scholar
• Džunková M, D’Auria G, Xu H, et al. The monoclonal antitoxin antibodies (Actoxumab–bezlotoxumab) treatment facilitates normalization of the gut microbiota of mice with Clostridium difficile infection. Front Cell Infect Microbiol. 2016;6. DOI:10.3389/fcimb.2016.00119
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305–317.
   PubMed Web of Science ®Google Scholar
• Thandavaram A, Channar A, Purohit A et al, et al., 2022 14 8 e27979 . The efficacy of bezlotoxumab in the prevention of recurrent Clostridium difficile: a systematic review. Cureus [].
   PubMed Web of Science ®Google Scholar
• Mileto SJ, Hutton ML, Walton SL, et al. Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection. Gut Microbes. 2022;14(1):2117504.
   PubMed Web of Science ®Google Scholar
• Prabhu VS, Dubberke ER, Dorr MB, et al. Cost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;66(3):355–362.
   PubMed Web of Science ®Google Scholar
• Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34(1):11–26.
   PubMed Web of Science ®Google Scholar
• Péchiné S, Janoir C, Collignon A. Emerging monoclonal antibodies against Clostridium difficile infection. Expert Opin Biol Ther. 2017;17(4):415–427.
   PubMed Web of Science ®Google Scholar
• Murase T, Eugenio L, Schorr M, et al. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J Biol Chem. 2014;289(4):2331–2343.
   PubMed Web of Science ®Google Scholar
• Yang Z, Schmidt D, Liu W, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. Infection Mice J Infect Dis. 2014;210(6):964–972.
   PubMed Web of Science ®Google Scholar
• Unger M, Eichhoff AM, Schumacher L, et al. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci Rep. 2015;5(1):1–10.
   Google Scholar
• Kandalaft H, Hussack G, Aubry A, et al. Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease. Appl Microbiol Biotechnol. 2015;99(20):8549–8562.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Granata G, Cataldo MA. Novel antimicrobials for the treatment of Clostridium difficile infection. Front Med. 2018;5. DOI:10.3389/fmed.2018.00096
   Web of Science ®Google Scholar
• Wiedemann I, Böttiger T, Bonelli RR, et al. The mode of action of the lantibiotic lacticin 3147 - a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol. 2006;61(2):285–296.
   PubMed Web of Science ®Google Scholar
• Rea M, Clayton E, O’Connor P et al, et al., 2007 56 Pt7 940–946 . Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Medical Microbiol. [cited 2022].
   PubMedGoogle Scholar
• Rea MC, Dobson A, O’Sullivan O, et al. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A. 2011;108():4639–4644.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Cornely OA, Grill S, et al. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis. 2019;19(3):265–274.
   PubMed Web of Science ®Google Scholar
• Rashid M-U, Lozano HM, Weintraub A, et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe. 2013;20:32–35.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother. 2012;56(6):3448–3452.
   PubMed Web of Science ®Google Scholar
• Daley P, Louie T, Lutz JE, et al. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. J Antimicrob Chemother. 2017;72(12):3462–3470.
   PubMed Web of Science ®Google Scholar
• Xu W-C, Silverman MH, Yu XY, et al. Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. Bioorg Med Chem. 2019;27(15):3209–3217.
   PubMed Web of Science ®Google Scholar
• Garey KW, McPherson J, Dinh AQ, et al. Efficacy, safety, pharmacokinetics, and microbiome changes of ibezapolstat in adults with Clostridioides difficile infection: a Phase 2a multicenter clinical trial. Clin Infect Dis. 2022;75(7):1164–1170.
   PubMed Web of Science ®Google Scholar
• McPherson J, Hu C, Begum K, et al. Functional and metagenomic evaluation of ibezapolstat for early evaluation of anti-recurrence effects in Clostridioides difficile infection. Antimicrob Agents Chemother. 2022;66(8). DOI:10.1128/aac.02244-21
   PubMed Web of Science ®Google Scholar
• Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017;17(7):735–744.
   PubMed Web of Science ®Google Scholar
• Collins DA, Wu Y, Tateda K, et al. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile. J Antimicrob Chemother. 2021;76(4):967–972.
   PubMed Web of Science ®Google Scholar
• Vickers R, Robinson N, Best E, et al. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis. 2015;15(1):91.
   PubMedGoogle Scholar
• Hutton ML, Pehlivanoglu H, Vidor CJ, et al. Repurposing auranofin as a Clostridioides difficile therapeutic. J Antimicrob Chemother. 2020;75:409–417.
   PubMed Web of Science ®Google Scholar
• Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54(1):211–216.
   PubMed Web of Science ®Google Scholar
• Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Med Clin North Am Antibacterial Ther Newer Agents. 2011;95(4):819–842.
   PubMed Web of Science ®Google Scholar
• Jump RLP, Kraft D, Hurless K, et al. Impact of Tigecycline versus other antibiotics on the fecal metabolome and on colonization resistance to Clostridium difficile in mice. PAI. 2017;2(1):1–20.
   Google Scholar
• Carlson PE, Kaiser AM, McColm SA, et al. Variation in germination of Clostridium difficile clinical isolates correlates to disease severity. Anaerobe. 2015;33:64–70.
   PubMed Web of Science ®Google Scholar
• Francis MB, Allen CA, Sorg JA. Muricholic acids inhibit Clostridium difficile spore germination and growth. PLoS One. 2013;8(9):e73653.
   PubMed Web of Science ®Google Scholar
• Shen E, Zhu K, Li D, et al. Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B. Commun Biol. 2020;3(1):1–8.
   PubMed Web of Science ®Google Scholar
• Sekulovic O, Bedoya MO, Fivian-Hughes AS, et al. The Clostridium difficile cell wall protein CwpV confers phase-variable phage resistance. Mol Microbiol. 2015;98(2):329–342.
   PubMed Web of Science ®Google Scholar